{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:25:08Z","timestamp":1783398308235,"version":"3.54.6"},"reference-count":120,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.autrev.2017.07.014","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T09:31:36Z","timestamp":1501579896000},"page":"1008-1015","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["How I treat juvenile idiopathic arthritis: A state of the art review"],"prefix":"10.1016","volume":"16","author":[{"given":"Rolando","family":"Cimaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achille","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2017.07.014_bb0005","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile idiopathic arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2017.07.014_bb0010","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.autrev.2016.09.012","article-title":"T cell subpopulations in juvenile idiopathic arthritis and their modifications after biotherapies","volume":"15","author":"Maggi","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.014_bb0015","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.autrev.2016.07.004","article-title":"Systemic-onset juvenile idiopathic arthritis","volume":"15","author":"Cimaz","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.014_bb0020","first-page":"390","article-title":"International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.014_bb0025","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1136\/annrheumdis-2012-201388","article-title":"It is time to rethink juvenile idiopathic arthritis classification and nomenclature","volume":"71","author":"Martini","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.014_bb0030","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nrrheum.2013.105","article-title":"Advances from clinical trials in juvenile idiopathic arthritis","volume":"9","author":"Lovell","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.014_bb0035","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/acr.20497","article-title":"Wallace American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis","volume":"63","author":"Wallace","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2017.07.014_bb0040","first-page":"126","article-title":"Optimisation of disease assessments in juvenile idiopathic arthritis","volume":"32","author":"Consolaro","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.014_bb0045","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12969-017-0138-4","article-title":"A comparison of three treatment strategies in recent onset non-systemic juvenile idiopathic arthritis: initial 3-months results of the BeSt for Kids-study","volume":"15","author":"Hissink Muller","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.autrev.2017.07.014_bb0055","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/art.34343","article-title":"Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis","volume":"64","author":"Wallace","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0060","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","article-title":"2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features","volume":"63","author":"Beukelman","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2017.07.014_bb0065","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.38092","volume":"65","author":"Ringold","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0070","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/art.20860","article-title":"A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results","volume":"52","author":"Ruperto","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0075","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1136\/adc.88.3.192","article-title":"Intra-articular corticosteroid injections in juvenile idiopathic arthritis","volume":"88","author":"Cleary","year":"2003","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.autrev.2017.07.014_bb0080","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1093\/rheumatology\/ker165","article-title":"Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis","volume":"50","author":"Lanni","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2017.07.014_bb0085","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/rheumatology\/keh313","article-title":"Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial","volume":"43","author":"Zulian","year":"2004","journal-title":"Rheumatology"},{"issue":"16","key":"10.1016\/j.autrev.2017.07.014_bb0090","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1056\/NEJM199204163261602","article-title":"Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The pediatric rheumatology collaborative study group and the cooperative children's study group","volume":"326","author":"Giannini","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2017.07.014_bb0095","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.20278","article-title":"Toward a better understanding of methotrexate","volume":"50","author":"Kremer","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0100","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0889-857X(05)70358-6","article-title":"The mechanism of action of methotrexate","volume":"23","author":"Cronstein","year":"1997","journal-title":"Rheum Dis Clin N Am"},{"key":"10.1016\/j.autrev.2017.07.014_bb0105","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/art.20288","article-title":"A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate","volume":"50","author":"Ruperto","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0110","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/ard.2007.073445","article-title":"The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis","volume":"67","author":"Bartoli","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.014_bb0115","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/acr.20069","article-title":"Clinical course and prognostic value of disease activity in the first two years in different subtypes of juvenile idiopathic arthritis","volume":"62","author":"Albers","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2017.07.014_bb0120","first-page":"1047","article-title":"Methotrexate bioavailability after oral and subcutaneous administration in children with juvenile idiopathic arthritis","volume":"27","author":"Tukova","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.014_bb0125","first-page":"179","article-title":"The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate","volume":"31","author":"Alsufyani","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.014_bb0130","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/rheumatology\/36.1.86","article-title":"Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis","volume":"36","author":"Hamilton","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.014_bb0135","first-page":"645","article-title":"Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis","volume":"31","author":"Hoekstra","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.014_bb0140","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0140-6736(17)30065-X","article-title":"Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial","volume":"389","author":"Ravelli","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2017.07.014_bb0145","first-page":"122","article-title":"The use of methotrexate in children with rheumatic diseases","volume":"28","author":"Gutierrez-Suarez","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.014_bb0150","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/art.20861","article-title":"Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular course juvenile rheumatoid arthritis (JRA)","volume":"52","author":"Silverman","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0155","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa041810","article-title":"Leflunomide or methotrexate for juvenile rheumatoid arthritis","volume":"352","author":"Silverman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2017.07.014_bb0160","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0022","article-title":"The biology and medical implications of interleukin-6","volume":"2","author":"Tanaka","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.autrev.2017.07.014_bb0165","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric rheumatology collaborative study group","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2017.07.014_bb0170","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/art.10885","article-title":"Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type","volume":"48","author":"Quartier","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0175","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1136\/ard.2003.014886","article-title":"The German etanercept registry for treatment of juvenile idiopathic arthritis","volume":"63","author":"Horneff","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.014_bb0180","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/art.24777","article-title":"Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis","volume":"60","author":"Giannini","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0185","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/rheumatology\/keq308","article-title":"Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients","volume":"50","author":"Southwood","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.07.014_bb0190","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/ard.2007.087593","article-title":"Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry","volume":"68","author":"Horneff","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.014_bb0195","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","article-title":"Preliminary definition of improvement in juvenile arthritis","volume":"40","author":"Giannini","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0200","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12969-016-0126-0","article-title":"Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept","volume":"14","author":"Verazza","year":"2016","journal-title":"Pediatr Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.014_bb0205","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/art.24516","article-title":"Development and validation of a composite disease activity score for juvenile idiopathic arthritis","volume":"61","author":"Consolaro","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0210","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/rheumatology\/keq292","article-title":"Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis","volume":"50","author":"Papsdorf","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.07.014_bb0215","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.2011.1671","article-title":"Factors associated with treatment response to etanercept in juvenile idiopathic arthritis","volume":"306","author":"Otten","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2017.07.014_bb0220","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1568-9972(03)00048-X","article-title":"The biology of TNF blockade","volume":"2","author":"Suryaprasad","year":"2003","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.014_bb0225","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1084\/jem.20151255","article-title":"Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF\u2013TNF-RII binding in rheumatoid arthritis","volume":"213","author":"Nguyen","year":"2016","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2017.07.014_bb0230","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2017.07.014_bb0235","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.38741","article-title":"Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry","volume":"66","author":"Schmeling","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0240","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0245","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.2009.100354","article-title":"Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension","volume":"69","author":"Ruperto","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.014_bb0250","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000450948","article-title":"Immunosuppressive activity of abatacept on circulating T helper lymphocytes from juvenile idiopathic arthritis patients","volume":"171","author":"Maggi","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.autrev.2017.07.014_bb0255","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2017.07.014_bb0260","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/art.27431","article-title":"Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis","volume":"62","author":"Ruperto","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0265","doi-asserted-by":"crossref","first-page":"432","DOI":"10.4161\/mabs.1.5.9497","article-title":"Tocilizumab","volume":"1","author":"Venkiteshwaran","year":"2009","journal-title":"MAbs"},{"key":"10.1016\/j.autrev.2017.07.014_bb0270","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","article-title":"Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial","volume":"74","author":"Brunner","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.014_bb0275","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/s10165-011-0481-0","article-title":"Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis","volume":"22","author":"Imagawa","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.014_bb0280","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.3899\/jrheum.100090","article-title":"Early predictors of juvenile sacroiliitis in enthesitis-related arthritis","volume":"37","author":"Pagnini","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.014_bb0285","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s10067-015-3029-4","article-title":"Enthesitis-related arthritis","volume":"34","author":"Aggarwal","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.014_bb0290","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/BF01450892","article-title":"Sulphasalazine in the treatment of children with chronic arthritis","volume":"17","author":"Huang","year":"1998","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.014_bb0295","first-page":"CD004800","article-title":"Sulfasalazine for ankylosing spondylitis (protocol)","volume":"3","author":"Chen","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2017.07.014_bb0300","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.39145","article-title":"Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis","volume":"67","author":"Horneff","year":"2015","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0305","first-page":"424","article-title":"Long-term outcome of anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondyloarthritis","volume":"32","author":"Hugle","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.014_bb0310","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.3899\/jrheum.110145","article-title":"Tumor necrosis factor\u2013blocking agents for children with enthesitis-related arthritis\u2014data from the Dutch Arthritis and Biologicals in Children Register, 1999\u20132010","volume":"38","author":"Otten","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.014_bb0315","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/annrheumdis-2012-203046","article-title":"Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study","volume":"73","author":"Horneff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.014_bb0320","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/acr.22657","article-title":"A randomized, double-blind, placebo-controlled multcenter study of adalimumab in pediatric patients with enthesitis-related arthritis","volume":"67","author":"Bugos-Vargas","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2017.07.014_bb0325","first-page":"w13582","article-title":"Systemic-onset juvenile idiopathic arthritis: the changing life of a rare disease","volume":"142","author":"Cimaz","year":"2012","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.autrev.2017.07.014_bb0330","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F","article-title":"Randomized, placebo-controlled, crossover trial of low- dose oral methotrexate in children with extended oligoarticular or systemic arthritis","volume":"43","author":"Woo","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0335","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/art.23437","article-title":"The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis","volume":"58","author":"Gattorno","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0340","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/RHU.0b013e3181a4f459","article-title":"Anakinra for systemic juvenile arthritis: the Rocky Mountain experience","volume":"15","author":"Zeft","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.014_bb0345","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANA-JIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.014_bb0350","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0355","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/art.38296","article-title":"Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study","volume":"66","author":"Vastert","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0360","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40259-015-0123-8","article-title":"Canakinumab: a review of its use in the management of systemic juvenile idiopathic arthritis","volume":"29","author":"Hoy","year":"2015","journal-title":"BioDrugs"},{"key":"10.1016\/j.autrev.2017.07.014_bb0365","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/art.33342","article-title":"A phase II study to evaluate dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features","volume":"64","author":"Ruperto","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0370","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2017.07.014_bb0375","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13075-016-1212-x","article-title":"Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy","volume":"19","author":"Brachat","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2017.07.014_bb0380","first-page":"203","article-title":"Is systemic juvenile rheumatoid arthritis an interleukin-6 mediated disease?","volume":"25","author":"De Benedetti","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.014_bb0385","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2017.07.014_bb0390","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2017.07.014_bb0395","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/14740338.2017.1303479","article-title":"Safety of tocilizumab in the treatment of juvenile idiopathic arthritis","volume":"16","author":"Machado","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.autrev.2017.07.014_bb0400","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/rheumatology\/kev382","article-title":"Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials","volume":"55","author":"Tarp","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.07.014_bb0405","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients","volume":"66","author":"Minoia","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0410","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/annrheumdis-2015-208982","article-title":"2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"75","author":"Ravelli","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.014_bb0415","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/rheumatology\/keq218","article-title":"Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients","volume":"50","author":"Miettunen","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.07.014_bb0420","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/art.39407","article-title":"Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab","volume":"68","author":"Grom","year":"2016","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0425","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3899\/jrheum.140288","article-title":"Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab","volume":"42","author":"Yokota","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.014_bb0430","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/rheumatology\/kev429","article-title":"Factors associated with choice of biologic among children with juvenile idiopathic arthritis: results from two UK paediatric biologic registers","volume":"55","author":"Kearsley-Fleet","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.autrev.2017.07.014_bb0435","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/rheumatology\/kev398","article-title":"Oliveira Ramos, et al. effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt","volume":"55","author":"Mour\u00e3o","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.07.014_bb0440","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.semarthrit.2016.07.001","article-title":"Biological agents in polyarticular juvenile idiopathic arthritis: a meta-analysis of randomized withdrawal trials","volume":"46","author":"Amarilyo","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0445","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13075-016-1170-3","article-title":"Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab","volume":"18","author":"Horneff","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2017.07.014_bb0450","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1136\/annrheumdis-2014-205372","article-title":"The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort","volume":"74","author":"Guzman","year":"2015","journal-title":"Ann Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0455","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1002\/art.30502","article-title":"Clinical outcomes after withdrawal of anti\u2013tumor necrosis factor a therapy in patients with juvenile idiopathic arthritis: a twelve-year experience","volume":"63","author":"Baszis","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0460","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2010.375","article-title":"Methotrexate withdrawal at 6 vs 12months in juvenile idiopathic arthritis in remission: a randomized clinical trial","volume":"303","author":"Foell","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2017.07.014_bb0465","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00296-013-2884-z","article-title":"Non-systemic juvenile idiopathic arthritis after reaching clinical remission with anti-TNFa therapy: a clinical practice observational study of patients who discontinued treatment","volume":"33","author":"Iglesias","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2017.07.014_bb0470","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1007\/s00296-012-2468-3","article-title":"Clinical remission in juvenile idiopathic arthritis after termination of etanercept","volume":"33","author":"Postepski","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2017.07.014_bb0475","first-page":"919","article-title":"A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission","volume":"28","author":"Pratsidou-Gertsi","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.014_bb0480","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.3899\/jrheum.100219","article-title":"Discontinuation of etanercept after successful treatment in patients with juvenile idiopathic arthritis","volume":"37","author":"Remesal","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.014_bb0485","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/1529-0131(200003)43:3<628::AID-ANR20>3.0.CO;2-X","article-title":"Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis","volume":"43","author":"Strey","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0490","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1136\/annrheumdis-2012-201329","article-title":"Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study","volume":"71","author":"Gerss","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.014_bb0495","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/rheumatology\/ket152","article-title":"A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8\/14 protein","volume":"52","author":"Moncrieffe","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.07.014_bb0500","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13075-015-0723-1","article-title":"MRP8\/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis","volume":"17","author":"Anink","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2017.07.014_bb0505","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/acr.22477","article-title":"Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy","volume":"67","author":"Chang","year":"2015","journal-title":"Arthritis Care Res"},{"issue":"Suppl. 10","key":"10.1016\/j.autrev.2017.07.014_bb0510","article-title":"Flares after withdrawal of biotherapies in JIA: clinical and laboratory correlates of remission duration [abstract]","volume":"68","author":"Simonini","year":"2016","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0515","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3899\/jrheum.161078","article-title":"Attitudes and approaches for withdrawing drugs for children with clinically inactive nonsystemic JIA: a survey of the childhood arthritis and rheumatology research alliance","volume":"44","author":"Horton","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.014_bb0520","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/BOR.0b013e328329c79d","article-title":"An update on methotrexate","volume":"21","author":"Braun","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.014_bb0525","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s11926-006-0041-3","article-title":"Update on the medical treatment of juvenile idiopathic arthritis","volume":"8","author":"Hashkes","year":"2006","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2017.07.014_bb0530","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1136\/annrheumdis-2011-200942","article-title":"Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis","volume":"71","author":"Bulatovic","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.014_bb0535","first-page":"CD000951","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","volume":"5","author":"Shea","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2017.07.014_bb0540","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1517\/14740338.2015.1042453","article-title":"Safety of biologic therapies for the treatment of juvenile idiopathic arthritis","volume":"14","author":"Horneff","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.autrev.2017.07.014_bb0545","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11926-015-0542-z","article-title":"Biologic-associated infections in pediatric rheumatology","volume":"17","author":"Horneff","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2017.07.014_bb0550","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s10067-011-1724-3","article-title":"Performance of tuberculin skin test and interferon gamma assay for the diagnosis of latent tuberculosis infection in juvenile idiopathic arthritis","volume":"30","author":"Camlar","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.014_bb0555","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/INF.0000000000001466","article-title":"Prebiologic therapy tuberculosis screening experience in a pediatric rheumatology center: TST and IGRA are both necessary","volume":"36","author":"Marino","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.autrev.2017.07.014_bb0560","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1203\/PDR.0b013e318208451d","article-title":"Exploring the binding sites of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab","volume":"69","author":"Kosma\u010d","year":"2011","journal-title":"Pediatr Res"},{"key":"10.1016\/j.autrev.2017.07.014_bb0565","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/03009742.2015.1022213","article-title":"Anti-adalimumab antibodies in juvenile idiopathic arthritis: frequent association with loss of response","volume":"44","author":"Skrabl-Baumgartner","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.014_bb0570","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/BOR.0000000000000301","article-title":"Targeting the interleukin-23\/17 axis in axial spondyloarthritis","volume":"28","author":"Paine","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.014_bb0575","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of- concept study (TOPAS)","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.014_bb0580","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2017.07.014_bb0585","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/art.38699","article-title":"Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis","volume":"66","author":"Ilowite","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0590","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/art.38042","article-title":"Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis","volume":"65","author":"Lovell","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.014_bb0595","first-page":"CD007356","article-title":"Rituximab for rheumatoid arthritis","author":"Lopez-Olivo","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2017.07.014_bb0600","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/01.bor.0000130286.54383.ea","article-title":"International research networks in pediatric rheumatology: the PRINTO perspective","volume":"16","author":"Ruperto","year":"2004","journal-title":"Curr Opin Rheumatol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997217301970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997217301970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T19:33:15Z","timestamp":1750793595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997217301970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":120,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1568997217301970"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2017.07.014","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How I treat juvenile idiopathic arthritis: A state of the art review","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2017.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}